Literature DB >> 31620114

Commentary: Tolerance and Resistance of Pseudomonas aeruginosa Biofilms to Antimicrobial Agents-How P. aeruginosa Can Escape Antibiotics.

Anaïs Soares1,2, François Caron1,3, Manuel Etienne1,3.   

Abstract

Entities:  

Keywords:  Pseudomonas aeruginosa; antibiotic failure; biofilm; phenotypic diversity; resistance; small colony variants; tolerance

Year:  2019        PMID: 31620114      PMCID: PMC6759825          DOI: 10.3389/fmicb.2019.02164

Source DB:  PubMed          Journal:  Front Microbiol        ISSN: 1664-302X            Impact factor:   5.640


× No keyword cloud information.
In a recent article published in Frontiers in Microbiology, Ciofu and Tolker-Nielsen (2019), offered a comprehensive and didactic review on how Pseudomonas aeruginosa escapes antibiotic therapy in biofilms through tolerance and resistance mechanisms. Though their paper provided a wide panorama of the current knowledge in this field, we assume that the role of small colony variants (SCV) regarding antibiotic failure could have been discussed. SCV are a phenotypic subset of the bacterial population surviving in biofilms. They have been described in chronic, persistent and recurrent biofilm-based infections, particularly in cystic fibrosis but also in chronic wound or device-related infections (Häussler et al., 2003; Proctor et al., 2006; Tielen et al., 2014; Johns et al., 2015). They were particularly well-described in Staphylococcus aureus (Proctor et al., 1995, 2006; von Eiff et al., 2006; Masoud-Landgraf et al., 2016), but were also identified in other species such as Pseudomonas aeruginosa (Häussler, 2004). P. aeruginosa SCV have a high biofilm-forming capacity and reduced swimming, swarming and twitching motilities (Déziel et al., 2001). They also have an increased expression of the psl and pel loci, encoding for Psl and Pel exopolysaccharides, that together with extracellular DNA form the biofilm matrix (Kirisits et al., 2005). Other studies reported that SCV emerged in biofilm cultures before any antibiotic exposure, and were not the sole bacterial population surviving antibiotic treatment (Déziel et al., 2001; Drenkard and Ausubel, 2002; Gloag et al., 2019). Because SCV constitute an adaptation of the parental strain to biofilm growth, contribute to biofilm production, and are encountered in situations where P. aeruginosa escapes antibiotics, their role in antibiotic failure through resistance mechanisms, tolerance mechanisms, or both can be questioned. Recently, Balaban et al. (2019) recalled the definitions of antibiotic resistance and antibiotic tolerance in a consensus statement. Resistance is the ability of bacteria to replicate in the presence of antibiotic, whereas tolerance is the capability of a population to survive exposure to a bactericidal antibiotic without an increase in the MIC. The combination of both mechanisms in biofilms, has been named “recalcitrance” by Lebeaux et al. (2014). In specific situations, the biofilm growth might favor the selection of resistant mutants. As a fact, the exopolysaccharide matrix might reduce the diffusion in the deepest layers of the biofilm of some antibiotics such as aminoglycosides (Tseng et al., 2013). Bacterial cells entrapped into the matrix might hence be exposed to sub-inhibitory antibiotic concentrations, and resistant mutants might emerge (Kohanski et al., 2010; Jørgensen et al., 2013). In a study by Drenkard and Ausubel (2002), P. aeruginosa SCV with higher MICs toward aminoglycosides were recovered in sputum samples of cystic fibrosis patients treated with aminoglycoside-based antibiotic regimen. The mechanism of such increase in the MIC for SCV was not elucidated. As compared to the parent strain, the reduced susceptibility of SCV to aminoglycosides might result from increased interactions between positively charged aminoglycosides and negatively charged matrix components such as extracellular DNA (Chiang et al., 2013). But in this study as well as in others, the MICs increased only for aminoglycosides and not for fluoroquinolones or β-lactams (Singh et al., 2009; Wei et al., 2011). However, the environmental conditions associated with biofilm growth (oxygen and nutrients limitations) mostly favor the expression of tolerance mechanisms (Walters et al., 2003; Borriello et al., 2004). Among the tolerant cells encountered in biofilms, persister cells are of particular interest (Lewis, 2010; Fauvart et al., 2011; Lebeaux et al., 2014). In various time-kill assays in P. aeruginosa biofilm models, a biphasic killing curve, the hallmark of persistence, was observed after antibiotic exposure (Mulcahy et al., 2010; Benthall et al., 2015; Rojo-Molinero et al., 2016). Despite prolonged exposure at high antibiotic doses, viable, and culturable cells were still present in the biofilm while no resistant mutant was detected. Using high doses of antibiotic known to diffuse in the depth of the biofilm, such as ciprofloxacin (Walters et al., 2003; Rodríguez-Martínez et al., 2007), it is likely that antibiotic concentrations rapidly exceeded the mutation prevention concentration, so that pre-existing spontaneous resistant mutants might be eradicated. Regarding tolerance, the role of SCV in biofilm has not been specifically studied even for S. aureus. Singh et al. (2009), in a membrane-supported biofilm model, observed the emergence of S. aureus SCV among persister cells after treatment with ciprofloxacin, but not after treatment with amikacin, cefotaxime, oxacillin, or vancomycin. To what extent SCV contribute to biofilm persistence remains unelucidated. From this analysis of the literature, we assume, in accordance with Ciofu and Tolker-Nielsen (2019) that resistance and tolerance mechanisms can both be expressed in biofilm infections. Those two ways for P. aeruginosa to escape antibiotics depend on different triggers. Sub-inhibitory antibiotic concentrations and active cell division favor the selection of genetically divergent resistant mutants. Conversely, lethal antibiotic concentrations trigger tolerance mechanisms, through a phenotypic adaptation, toward what could be called the “last hope bacterial response for survival” (Fajardo and Martínez, 2008; Andersson and Hughes, 2014). This phenotypic adaptation combines stress response activation depending on starvation strategies such as stringent response, SOS response or other metabolic pathways (Harms et al., 2016). SCV are part of these antibiotic-recalcitrant biofilm and for sure have specific metabolic characteristics, the increased exopolysaccharide matrix production being at the forefront (Harmsen et al., 2010; Moradali et al., 2017). Whether SCV behave differently than their parental strain regarding resistant mutants or persister cells emergence can to date not be ensured and needs further investigation. However, SCV might play a key role in the expression of persistence mechanisms, through their part in the biofilm structure, and may largely contribute to the environmental conditions associated with antibiotic recalcitrance. In a daily practice, P. aeruginosa SCV can be detected on plate cultures. In most cases, they attest the presence of biofilm-related infection. SCV testing with usual antimicrobial susceptibility testing methods is also feasible, but little difference is expected regarding antimicrobial susceptibility between SCV and other bacterial populations entrapped in the biofilm. Nevertheless, informing clinicians of the presence of SCV seems crucial, as a signal that conditions are gathered for P. aeruginosa to escape antibiotics.

Author Contributions

FC suggested the general commentary and reviewed the manuscript. AS and ME reviewed the literature and wrote the manuscript. All authors listed approved the work for publication.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
  34 in total

Review 1.  Persister cells.

Authors:  Kim Lewis
Journal:  Annu Rev Microbiol       Date:  2010       Impact factor: 15.500

2.  Activity and penetration of fosfomycin, ciprofloxacin, amoxicillin/clavulanic acid and co-trimoxazole in Escherichia coli and Pseudomonas aeruginosa biofilms.

Authors:  José M Rodríguez-Martínez; Sofía Ballesta; Alvaro Pascual
Journal:  Int J Antimicrob Agents       Date:  2007-07-05       Impact factor: 5.283

Review 3.  Antibiotics as signals that trigger specific bacterial responses.

Authors:  Alicia Fajardo; José L Martínez
Journal:  Curr Opin Microbiol       Date:  2008-03-25       Impact factor: 7.934

4.  Initiation of biofilm formation by Pseudomonas aeruginosa 57RP correlates with emergence of hyperpiliated and highly adherent phenotypic variants deficient in swimming, swarming, and twitching motilities.

Authors:  E Déziel; Y Comeau; R Villemur
Journal:  J Bacteriol       Date:  2001-02       Impact factor: 3.490

5.  Sequential Treatment of Biofilms with Aztreonam and Tobramycin Is a Novel Strategy for Combating Pseudomonas aeruginosa Chronic Respiratory Infections.

Authors:  Estrella Rojo-Molinero; María D Macià; Rosa Rubio; Bartolomé Moyà; Gabriel Cabot; Carla López-Causapé; José L Pérez; Rafael Cantón; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 6.  The small colony variant (SCV) concept -- the role of staphylococcal SCVs in persistent infections.

Authors:  Christof von Eiff; Georg Peters; Karsten Becker
Journal:  Injury       Date:  2006-05       Impact factor: 2.586

7.  Extracellular DNA shields against aminoglycosides in Pseudomonas aeruginosa biofilms.

Authors:  Wen-Chi Chiang; Martin Nilsson; Peter Østrup Jensen; Niels Høiby; Thomas E Nielsen; Michael Givskov; Tim Tolker-Nielsen
Journal:  Antimicrob Agents Chemother       Date:  2013-03-11       Impact factor: 5.191

8.  Sublethal ciprofloxacin treatment leads to rapid development of high-level ciprofloxacin resistance during long-term experimental evolution of Pseudomonas aeruginosa.

Authors:  Karin Meinike Jørgensen; Tina Wassermann; Peter Østrup Jensen; Wang Hengzuang; Søren Molin; Niels Høiby; Oana Ciofu
Journal:  Antimicrob Agents Chemother       Date:  2013-06-17       Impact factor: 5.191

9.  Phenotypic and genome-wide analysis of an antibiotic-resistant small colony variant (SCV) of Pseudomonas aeruginosa.

Authors:  Qing Wei; Saeed Tarighi; Andreas Dötsch; Susanne Häussler; Mathias Müsken; Victoria J Wright; Miguel Cámara; Paul Williams; Steven Haenen; Bart Boerjan; Annelies Bogaerts; Evy Vierstraete; Peter Verleyen; Liliane Schoofs; Ronnie Willaert; Valérie N De Groote; Jan Michiels; Ken Vercammen; Aurélie Crabbé; Pierre Cornelis
Journal:  PLoS One       Date:  2011-12-15       Impact factor: 3.240

Review 10.  Definitions and guidelines for research on antibiotic persistence.

Authors:  Nathalie Q Balaban; Sophie Helaine; Kim Lewis; Martin Ackermann; Bree Aldridge; Dan I Andersson; Mark P Brynildsen; Dirk Bumann; Andrew Camilli; James J Collins; Christoph Dehio; Sarah Fortune; Jean-Marc Ghigo; Wolf-Dietrich Hardt; Alexander Harms; Matthias Heinemann; Deborah T Hung; Urs Jenal; Bruce R Levin; Jan Michiels; Gisela Storz; Man-Wah Tan; Tanel Tenson; Laurence Van Melderen; Annelies Zinkernagel
Journal:  Nat Rev Microbiol       Date:  2019-07       Impact factor: 60.633

View more
  2 in total

1.  Bidirectional alterations in antibiotics susceptibility in Staphylococcus aureus-Pseudomonas aeruginosa dual-species biofilm.

Authors:  Elena Y Trizna; Maria N Yarullina; Diana R Baidamshina; Anna V Mironova; Farida S Akhatova; Elvira V Rozhina; Rawil F Fakhrullin; Alsu M Khabibrakhmanova; Almira R Kurbangalieva; Mikhail I Bogachev; Airat R Kayumov
Journal:  Sci Rep       Date:  2020-09-09       Impact factor: 4.379

2.  The Flagellar Transcriptional Regulator FtcR Controls Brucella melitensis 16M Biofilm Formation via a betI-Mediated Pathway in Response to Hyperosmotic Stress.

Authors:  Jia Guo; Xingmei Deng; Yu Zhang; Shengnan Song; Tianyi Zhao; Dexin Zhu; Shuzhu Cao; Peter Ivanovic Baryshnikov; Gang Cao; Hugh T Blair; Chuangfu Chen; Xinli Gu; Liangbo Liu; Hui Zhang
Journal:  Int J Mol Sci       Date:  2022-08-31       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.